PADI4 and breast cancer: In an ER+ MCF-7 breast cancer model, the stable knockdown of PAD4 led to a decreased nuclear GSK3β level, activation of TGF-β signaling and the EMT, thereby enhancing the invasive potential of breast cancer cells [89].